First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Company profile
Ticker
ENTO
Exchange
Website
CEO
Mr. James R. Sapirstein M.B.A., R.Ph.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
AzurRx BioPharma, Inc., BioPharma d'Azur, Inc., First Wave BioPharma, Inc.
SEC CIK
Corporate docs
Subsidiaries
First Wave Bio, Inc. • ImmunogenX, LLC ...
ENTO stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
11 Sep 24
8-K
Regulation FD Disclosure
10 Sep 24
8-K
Other Events
3 Sep 24
8-K
Changes in Registrant's Certifying Accountant
29 Aug 24
8-K
Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q
23 Aug 24
8-K
Departure of Directors or Certain Officers
22 Aug 24
NT 10-Q
Notice of late quarterly filing
15 Aug 24
8-K
Changes in Registrant's Certifying Accountant
15 Aug 24
8-K
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
7 Aug 24
8-K
Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program
31 Jul 24
Transcripts
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.45 mm | 3.45 mm | 3.45 mm | 3.45 mm | 3.45 mm | 3.45 mm |
Cash burn (monthly) | 93.29 k | (no burn) | 3.10 mm | 1.75 mm | 1.25 mm | 1.11 mm |
Cash used (since last report) | 584.11 k | n/a | 19.39 mm | 10.96 mm | 7.82 mm | 6.93 mm |
Cash remaining | 2.87 mm | n/a | -15.94 mm | -7.50 mm | -4.37 mm | -3.48 mm |
Runway (months of cash) | 30.8 | n/a | -5.1 | -4.3 | -3.5 | -3.1 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jul 24 | Sapirstein James | Common Stock | Sell | Dispose S | No | No | 1.07 | 1,289 | 1.38 k | 35,816 |
2 Jul 24 | Romano Sarah | Common Stock | Sell | Dispose S | No | No | 1.07 | 621 | 664.47 | 18,490 |
11 Jun 24 | Khosla Chaitan PHD | Common Stock | Grant | Acquire A | No | No | 0 | 24,889 | 0.00 | 24,889 |
1 Apr 24 | Romano Sarah | Common Stock | Sell | Dispose S | No | No | 4.2294 | 75 | 317.21 | 19,111 |
News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
8 Oct 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
7 Oct 24
12 Health Care Stocks Moving In Friday's After-Market Session
4 Oct 24
12 Health Care Stocks Moving In Friday's Intraday Session
4 Oct 24
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
16 Sep 24
Press releases
Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board
8 Oct 24
Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings
10 Sep 24
Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q
23 Aug 24
Entero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program
31 Jul 24